...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: 0.05 P-values -- A bridge too far ?

So after all is said and done it sounds like a new P3 would be the fastest most economical route to market. If you take into consideration that the trial could be halted for ethical reasons (like the drug working to well with more design targets like SGLT2's, DPP4's and more patients with lower functioning kidney's) there is a reasonable chance a new NDA could be in the process of being filed in 24 to 30 months.

I'm okay with that. 

There is also a chance that a BP partner may not want to wait for results before pulling the trigger.

tada

Share
New Message
Please login to post a reply